Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aridis Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.01.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aridis Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.
The historical rank and industry rank for Aridis Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
ARDS's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.17 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Aridis Pharmaceuticals Cash-to-Debt Related Terms
Aridis Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Aridis Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aridis Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals (ARDS) has a Cash-to-Debt of 0.01 as of Sep. 2023.
Is Aridis Pharmaceuticals' Cash-to-Debt too high?
Aridis Pharmaceuticals' current Cash-to-Debt is 0.01. The Biotechnology industry median Cash-to-Debt is 7.17. Aridis Pharmaceuticals' value of 0.01 is 99.9% below this industry median. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Cash-to-Debt compare to ARTL and REVB?
Aridis Pharmaceuticals' Cash-to-Debt of 0.01 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.17. Aridis Pharmaceuticals' value of 0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aridis Pharmaceuticals's current Cash-to-Debt of 0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aridis Pharmaceuticals's current Cash-to-Debt is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Cash-to-Debt of 0.01. The current Cash-to-Debt is 0.01 and 99.9% below the Biotechnology industry median of 7.17. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Cash-to-Debt is 0.01 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score
Get the complete analysis for ARDS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDS has been successfully added to your 
